Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
- 5 June 2008
- journal article
- Published by Elsevier in Virus Research
- Vol. 136 (1-2) , 75-80
- https://doi.org/10.1016/j.virusres.2008.04.020
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell LinesJournal of Virology, 2007
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell DeathJournal of Virology, 2006
- The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cellsJournal of Cellular Biochemistry, 2006
- MTH-68/H Oncolytic Viral Treatment in Human High-Grade GliomasJournal of Neuro-Oncology, 2004
- Effect of Coexpression of Interleukin-2 by Recombinant Respiratory Syncytial Virus on Virus Replication, Immunogenicity, and Production of Other CytokinesJournal of Virology, 2000
- A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysateCancer, 1983
- Reconstitution studies detect a single polymerase entry site on the vesicular stomatitis virus genomeCell, 1982
- VIRUSES IN THE TREATMENT OF CANCERThe Lancet, 1971
- Newcastle disease virus as an antineoplastic agentCancer, 1965